Oud Lavi
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Texas Tech University Health Sciences Center at the Permian Basin, Odessa, TX, USA. Email:
J Clin Med Res. 2023 Dec;15(10-11):438-445. doi: 10.14740/jocmr5027. Epub 2023 Dec 9.
The surge in critical illness and associated mortality brought by the coronavirus virus disease 2019 (COVID-19) pandemic, coupled with staff shortages and restrictions of family visitation, may have adversely affected delivery of palliative measures, including at the end of life of affected patients. However, the population-level patterns of palliative care (PC) utilization among septic critically ill patients with and without COVID-19 during end-of-life hospitalizations are unknown.
A statewide dataset was used to identify patients aged ≥ 18 years with intensive care unit (ICU) admission and a diagnosis of sepsis in Texas, who died during hospital stay during April 1 to December 31, 2020. COVID-19 was defined by the International Classification of Diseases, 10th Revision (ICD-10) code U07.1, and PC was identified by ICD-10 code Z51.5. Multivariable logistic models were fitted to estimate the association of COVID-19 with use of PC among ICU admissions. A similar approach was used for sensitivity analyses of strata with previously reported lower and higher than reference use of PC.
There were 20,244 patients with sepsis admitted to ICU during terminal hospitalization, and 9,206 (45.5%) had COVID-19. The frequency of PC among patients with and without COVID-19 was 32.0% vs. 37.1%, respectively. On adjusted analysis, the odds of PC use remained lower among patients with COVID-19 (adjusted odds ratio (aOR): 0.84, 95% confidence interval (CI): 0.78 - 0.90), with similar findings on sensitivity analyses.
PC was markedly less common among critically ill septic patients with COVID-19 during terminal hospitalization, compared to those without COVID-19. Further studies are needed to determine the factors underlying these findings in order to reduce disparities in use of PC.
2019年冠状病毒病(COVID-19)大流行带来的危重症激增及相关死亡率上升,再加上人员短缺和家属探视限制,可能对姑息治疗措施的实施产生了不利影响,包括在受影响患者的临终阶段。然而,在临终住院期间,合并和未合并COVID-19的脓毒症危重症患者中姑息治疗(PC)的人群水平使用模式尚不清楚。
使用德克萨斯州的全州数据集,识别2020年4月1日至12月31日期间入住重症监护病房(ICU)且诊断为脓毒症、年龄≥18岁且在住院期间死亡的患者。COVID-19由国际疾病分类第十版(ICD-10)编码U07.1定义,PC由ICD-10编码Z51.5识别。采用多变量逻辑模型估计ICU入院患者中COVID-19与PC使用之间的关联。对PC使用低于和高于参考值的分层进行敏感性分析时采用了类似方法。
在临终住院期间,有20244例脓毒症患者入住ICU,其中9206例(45.5%)患有COVID-19。合并和未合并COVID-19患者的PC使用频率分别为32.0%和37.1%。经调整分析,COVID-19患者使用PC的几率仍然较低(调整后的优势比(aOR):0.84,95%置信区间(CI):0.78 - 0.90),敏感性分析结果相似。
与未感染COVID-19的危重症脓毒症患者相比,感染COVID-19的危重症脓毒症患者在临终住院期间接受PC的情况明显较少。需要进一步研究以确定这些发现背后的因素,以减少PC使用方面的差异。